Literature DB >> 26201326

Bacterial infections in cirrhosis.

Gregory J Botwin1,2, Timothy R Morgan3,4.   

Abstract

Bacterial infections occur in 25-35 % of cirrhotics admitted to hospital. Health-care associated and hospital acquired (nosocomial) infections are the most common epidemiology, with community acquired infections less common (15-30 %). Spontaneous bacterial peritonitis and urinary infections are the most common sites, with spontaneous bacteremia, pneumonia, cellulitis and other sites being less common. The risk of infection is increased among subjects with more severe liver disease and an infection in the past 6 months. Bacteria are isolated from approximately half of patients with a clinical diagnosis of infection. Gram-negative enterobacteriaceae are the most common organisms among community acquired infections; Gram-positive cocci are the most common organisms isolated among subjects with nosocomial infections. Up to 30 % of hospital associated infections are with multidrug resistant bacteria. Consequently, empiric antibiotic therapy that is recommended for community acquired infections is often inadequate for nosocomial infections. Infections worsen liver function. In-hospital and 1-year mortality of cirrhotics with infections is significantly higher than among cirrhotics without infection. In-hospital complications of infections, such as severe sepsis and septic shock, and mortality, are increased among subjects with multidrug-resistant infections as compared with cirrhotics with susceptible bacteria. Short-term antibiotic prophylaxis of cirrhotics with upper gastrointestinal bleeding and long-term antibiotic prophylaxis of selected cirrhotics with spontaneous bacterial peritonitis reduces infections and improves survival. Albumin administration to cirrhotics with SBP and evidence of advanced liver disease improves survival. The benefit of albumin administration to cirrhotics with infections other than SBP is under investigation.

Entities:  

Keywords:  Antibiotics; Cirrhosis; Infection; Multidrug-resistant bacteria; Sepsis; Survival

Year:  2014        PMID: 26201326     DOI: 10.1007/s12072-014-9522-z

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  29 in total

1.  Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage.

Authors:  J Goulis; A Armonis; D Patch; C Sabin; L Greenslade; A K Burroughs
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

2.  Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study.

Authors:  Javier Fernández; Juan Acevedo; Miriam Castro; Orlando Garcia; Carlos Rodríguez de Lope; Daria Roca; Marco Pavesi; Elsa Sola; Leticia Moreira; Anibal Silva; Tiago Seva-Pereira; Francesco Corradi; Jose Mensa; Pere Ginès; Vicente Arroyo
Journal:  Hepatology       Date:  2012-04-04       Impact factor: 17.425

3.  Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.

Authors:  Javier Fernández; Miquel Navasa; Juliá Gómez; Jordi Colmenero; Jordi Vila; Vicente Arroyo; Juan Rodés
Journal:  Hepatology       Date:  2002-01       Impact factor: 17.425

4.  Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis.

Authors:  B Bernard; J D Grangé; E N Khac; X Amiot; P Opolon; T Poynard
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

5.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.

Authors:  Vasiliki Arvaniti; Gennaro D'Amico; Giuseppe Fede; Pinelopi Manousou; Emmanuel Tsochatzis; Maria Pleguezuelo; Andrew Kenneth Burroughs
Journal:  Gastroenterology       Date:  2010-06-14       Impact factor: 22.682

6.  Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor.

Authors:  Alexandre Louvet; Faustine Wartel; Hélène Castel; Sébastien Dharancy; Antoine Hollebecque; Valérie Canva-Delcambre; Pierre Deltenre; Philippe Mathurin
Journal:  Gastroenterology       Date:  2009-05-13       Impact factor: 22.682

7.  A prospective study of bacterial infections in patients with cirrhosis.

Authors:  W R Caly; E Strauss
Journal:  J Hepatol       Date:  1993-07       Impact factor: 25.083

8.  Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure.

Authors:  Dominique Thabut; Julien Massard; Alice Gangloff; Nicolas Carbonell; Claire Francoz; Eric Nguyen-Khac; Christian Duhamel; Didier Lebrec; Thierry Poynard; Richard Moreau
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

9.  Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study.

Authors:  Rubén Terg; Eduardo Fassio; Mónica Guevara; Mariano Cartier; Cristina Longo; Romina Lucero; Cristina Landeira; Gustavo Romero; Nora Dominguez; Alberto Muñoz; Diana Levi; Carlos Miguez; Raquel Abecasis
Journal:  J Hepatol       Date:  2008-02-14       Impact factor: 25.083

10.  Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence.

Authors:  Tilman M Bauer; Antonio Follo; Miguel Navasa; Jordi Vila; Ramon Planas; Gerardo Clemente; Victor Vargas; Felipe Bory; Pere Vaquer; Juan Rodés
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

View more
  6 in total

1.  Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation.

Authors:  Allison Mah; Alissa Wright
Journal:  Curr Infect Dis Rep       Date:  2016-01       Impact factor: 3.725

2.  Investigation on outcomes and bacterial distributions of liver cirrhosis patients with gram-negative bacterial bloodstream infection.

Authors:  Yangxin Xie; Bo Tu; Xin Zhang; Jingfeng Bi; Lei Shi; Peng Zhao; Weiwei Chen; Suxia Liu; Dongping Xu; Enqiang Qin
Journal:  Oncotarget       Date:  2017-12-22

3.  Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: a nested case-control study.

Authors:  Veronika Fedirko; Hao Quang Tran; Andrew T Gewirtz; Magdalena Stepien; Antonia Trichopoulou; Krasimira Aleksandrova; Anja Olsen; Anne Tjønneland; Kim Overvad; Franck Carbonnel; Marie-Christine Boutron-Ruault; Gianluca Severi; Tilman Kühn; Rudolf Kaaks; Heiner Boeing; Christina Bamia; Pagona Lagiou; Sara Grioni; Salvatore Panico; Domenico Palli; Rosario Tumino; Alessio Naccarati; Petra H Peeters; H B Bueno-de-Mesquita; Elisabete Weiderpass; José María Huerta Castaño; Aurelio Barricarte; María-José Sánchez; Miren Dorronsoro; J Ramón Quirós; Antonio Agudo; Klas Sjöberg; Bodil Ohlsson; Oskar Hemmingsson; Mårten Werner; Kathryn E Bradbury; Kay-Tee Khaw; Nick Wareham; Konstantinos K Tsilidis; Dagfinn Aune; Augustin Scalbert; Isabelle Romieu; Elio Riboli; Mazda Jenab
Journal:  BMC Med       Date:  2017-04-04       Impact factor: 8.775

Review 4.  Management of Antimicrobial Agents in Abdominal Organ Transplant Patients in Intensive Care Unit.

Authors:  Aaron Kaviani; Dilek Ince; David A Axelrod
Journal:  Curr Transplant Rep       Date:  2020-01-24

5.  Pneumonia in patients with cirrhosis: risk factors associated with mortality and predictive value of prognostic models.

Authors:  Lichen Xu; Shuangwei Ying; Jianhua Hu; Yunyun Wang; Meifang Yang; Tiantian Ge; Chunhong Huang; Qiaomai Xu; Haihong Zhu; Zhi Chen; Weihang Ma
Journal:  Respir Res       Date:  2018-12-04

6.  Multivariate predictive model for asymptomatic spontaneous bacterial peritonitis in patients with liver cirrhosis.

Authors:  Bo Tu; Yue-Ning Zhang; Jing-Feng Bi; Zhe Xu; Peng Zhao; Lei Shi; Xin Zhang; Guang Yang; En-Qiang Qin
Journal:  World J Gastroenterol       Date:  2020-08-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.